Amedisys Finalizes Settlement Agreement With Government

Amedisys Finalizes Settlement Agreement With Government

Settlement Brings Previously Announced DOJ Civil Investigation and Stark Law
Self -Referral Disclosure to a Close

BATON ROUGE, La., April 23, 2014 (GLOBE NEWSWIRE) -- Amedisys, Inc.
(Nasdaq:AMED), one of America's leading home health and hospice care
companies, announced today that the company has finalized its previously
announced settlement to bring to an end the civil investigation brought by the
U.S. Department of Justice ("DOJ").

Amedisys has fully cooperated with the DOJ civil investigation, which involved
Medicare reimbursement for home health services provided by certain Amedisys
care centers from January 1, 2008 through December 31, 2010. The settlement
also resolves a previously disclosed Stark Law issue regarding care
coordination services provided to a physician practice group in exchange for
compensation that was not consistent with fair market value during the period
April 1, 2008 through April 30, 2012, which the company voluntarily
self-disclosed to the Centers for Medicare and Medicaid Services.

As previously announced, although Amedisys disputed the DOJ's allegations of
misconduct, it decided to settle to avoid the cost and uncertainty inherent in
protracted litigation. The DOJ investigation primarily centered on
determinations made by Amedisys clinicians and independent physicians that
patients were homebound and needed skilled nursing or therapy services, and
that the services provided were medically necessary. Each year, Amedisys'
dedicated clinicians provide care to more than 360,000 patients, many of whom
suffer from more than one chronic and debilitating disease.

Amedisys maintains that it operated according to stringent policies requiring
that home health nursing and therapy services be delivered to qualifying
patients having a medical need for such care, and only upon the direction of
their physicians. Amedisys provides extensive training to its clinicians
concerning these requirements and has made significant investments in its
compliance program, which has been designed to comport with guidelines
established by the Office of Inspector General, United States Department of
Health and Human Services. The final Settlement Agreement reflects Amedisys'
disagreement with the DOJ's claims and includes no admission or determination
of wrongdoing.

"We are pleased to put this matter behind us," stated Ronald A. LaBorde,
President and Interim Chief Executive Officer. "We are intensely focused on
achieving the best possible outcomes for our patients by providing the care
they need, when they need it, in the comfort of their own homes. We strive
diligently to ensure that our operations are fully compliant with Medicare
program requirements."

Under the terms of the civil settlement, and as disclosed previously, Amedisys
will pay a total of $150 million plus interest in two installments.The first
installment of $115 million plus interest must be paid by May 2, 2014, and the
remaining $35 million plus interest must be paid by October 23, 2014.The
company will fund the settlement through cash on hand and draws upon its
existing credit facility.

Amedisys took the charge associated with the settlement in the third quarter
of 2013.In addition to the amount to be paid to the United States, the
company will be responsible for payment of attorneys' fees and expenses of
various qui tam relators in the amount of approximately $3.9 million, which
will be recorded in the first quarter of 2014.

About Amedisys:

Amedisys, Inc. (Nasdaq:AMED) is a "health care at home" company delivering
personalized home health and hospice care to more than 360,000 patients each
year. Amedisys is focused on delivering the care that is best for our
patients, whether that is home-based recovery and rehabilitation after an
operation or injury, care focused on empowering them to manage a chronic
disease, palliative care for those with a terminal illness, or hospice care at
the end of life. For more information about Amedisys, please visit:
http://www.amedisys.com.

We use our company website as a channel of distribution for important company
information. Important information, including press releases, analyst
presentations and financial information regarding the Company is routinely
posted on and accessible on the "Investor Relations" subpage of our website,
which is accessible by clicking on the tab labeled "Investors" on our website
home page. We will also use our website to expedite public access to
time-critical information regarding the Company in advance of or in lieu of
distributing a press release or a filing with the Securities and Exchange
Commission ("SEC") disclosing the same information. In addition, we make
available on the Investor Relations subpage of our website (under the link
"SEC filings") free of charge our annual reports on Form 10-K, quarterly
reports on Form 10-Q, current reports on Form 8-K, ownership reports on Forms
3, 4 and 5 and any amendments to those reports as soon as practicable after we
electronically file such reports with the SEC. Further, copies of our
Certificate of Incorporation and Bylaws, our Code of Ethical Business Conduct
and the charters for the Audit, Compensation, Nominating and Corporate
Governance, Quality of Care and Compliance and Ethics Committees of our Board
are also available on the Investor Relations subpage of our website (under the
link "Corporate Governance").

Certain Forward-Looking Statements

This press release includes forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements involve a variety of risks and uncertainties that could cause
actual results to differ materially from those described therein. These risks
and uncertainties include, but are not limited to the following: changes in
Medicare and other medical payment levels, our ability to open care centers,
acquire additional care centers and integrate and operate these care centers
effectively, our ability to divest care centers currently held for sale,
changes in or our failure to comply with existing Federal and State laws or
regulations or the inability to comply with new government regulations on a
timely basis, competition in the home health industry, changes in the case mix
of patients and payment methodologies, changes in estimates and judgments
associated with critical accounting policies, our ability to maintain or
establish new patient referral sources, our ability to attract and retain
qualified personnel, changes in payments and covered services due to the
economic downturn and deficit spending by Federal and state governments,
future cost containment initiatives undertaken by third-party payors, our
access to financing due to the volatility and disruption of the capital and
credit markets, our ability to meet debt service requirements and comply with
covenants in debt agreements, business disruptions due to natural disasters or
acts of terrorism, our ability to integrate and manage our information
systems, our ability to comply with the terms of our settlement agreement and
corporate integrity agreement entered into with the United States government,
and changes in law or developments with respect to any litigation or
investigations relating the Company, including the SEC investigation, the OIG
Self-Disclosure issues and various other matters, many of which are beyond our
control.

Because forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified, you should not
rely on any forward-looking statement as a prediction of future events. We
expressly disclaim any obligation or undertaking and we do not intend to
release publicly any updates or changes in our expectations concerning the
forward-looking statements or any changes in events, conditions or
circumstances upon which any forward-looking statement may be based, except as
required by law.

CONTACT: Amedisys, Inc.
         Media Relations:
         Shannon McIntyre Hooper, 615-577-1124
         smh@thinkrevivehealth.com
         or
         Investor Relations:
         David Castille, 225-299-3665
         Director - Treasury/Finance
         david.castille@amedisys.com

Amedisys, Inc. logo
 
Press spacebar to pause and continue. Press esc to stop.